Form 4 for SION Sionna Therapeutics, Inc.
Accepted 2025-09-30 00:00:00 ET · period of report 2025-09-26 · accession 0001704336-25-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-09-30 | 2025-09-26+ | SION | Cloonan Michael | Pres, CEO, Dir | M - OptEx | $6.11 | +25.0K | 564.5K | +5% | +$152.8K |
| DM | 2025-09-30 | 2025-09-26+ | SION | Cloonan Michael | Pres, CEO, Dir | S - Sale+OE | $29.11 | -25.0K | 547.3K | -4% | -$727.9K |
| DM | 2025-09-30 | 2025-09-26+ | SION | Cloonan Michael | Pres, CEO, Dir | M - OptEx | $0.00 | -25.0K | 185.9K | -12% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-09-29 | M | A | 7,793 | $6.11 | 555,136 | D | — | — | |
| 2 | Common | Common Stock | 2025-09-26 | S | D | 17,207 | $28.85 | 547,343 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.75 to $28.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. |
| 3 | Common | Common Stock | 2025-09-26 | M | A | 17,207 | $6.11 | 564,550 | D | — | — | |
| 4 | Common | Common Stock | 2025-09-29 | S | D | 7,793 | $29.70 | 547,343 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.83 to $29.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. |
| 5 | Derivative | Non-Qualified Stock Option (right to buy) | 2025-09-29 | M | D | 7,793 | $0.00 | 178,142 | D | $6.11 · — to 2032-03-01 | 7,793 Common Stock | (F4) The shares underlying this option vest in forty-eight equal monthly installments following February 2, 2022, subject to the Reporting Person's continued service on each such vesting date. |
| 6 | Derivative | Non-Qualified Stock Option (right to buy) | 2025-09-26 | M | D | 17,207 | $0.00 | 185,935 | D | $6.11 · — to 2032-03-01 | 17,207 Common Stock | (F4) The shares underlying this option vest in forty-eight equal monthly installments following February 2, 2022, subject to the Reporting Person's continued service on each such vesting date. |